Strong growth across India and North America, a robust respiratory pipeline, and upcoming launches keep Motilal Oswal constructive on Glenmark Pharma despite a marginal cut in earnings estimates.
Strong growth across India and North America, a robust respiratory pipeline, and upcoming launches keep Motilal Oswal constructive on Glenmark Pharma despite a marginal cut in earnings estimates.
<iframe src="https://hindustansphere.com/embed/cluster/27fc07a3a72204eaed768ac9e59a445dcb11e21c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Glenmark Pharma's India-US Growth Story Intact, Says Motilal Oswal, Maintaining 'Buy' — Check Target Price"></iframe>
